Why Farbe Firma is the Top Manufacturer of Tolperisone Lidocaine Injection
- Maulik Sudani
- Jun 24
- 8 min read
Last Updated: June 24, 2026
TL;DR: Tolperisone Lidocaine Injection — a sterile, clear, colourless aqueous solution that combines tolperisone hydrochloride, a centrally acting muscle relaxant that lowers pathologically increased muscle tone, with a small amount of lidocaine hydrochloride added to ease the discomfort of intramuscular injection, supplied commonly as 100 mg tolperisone with 2.5 mg lidocaine per 1 mL ampoule given by deep intramuscular injection — is a widely used medicine for the relief of painful muscle spasm and the spasticity that accompanies neurological and musculoskeletal disorders. Because the product is a fixed-dose combination of two actives delivered parenterally, each ampoule must deliver an exact, sterile, particulate-free dose of both tolperisone and lidocaine at the labelled strengths, with the dual-active stability-indicating assay, the related-substance profile of each active, solution pH, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Tolperisone Lidocaine Injection at our Gujarat, India facility and supplies it to neurology, rehabilitation, orthopaedic and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Centrally acting muscle relaxant combined with a local anaesthetic — tolperisone lowers pathologically raised muscle tone through a central, membrane-stabilising action, while the added lidocaine eases injection-site pain, and Tolperisone Lidocaine Injection (100 mg + 2.5 mg per mL, deep intramuscular) relieves painful muscle spasm and spasticity, where an exact, reproducible parenteral dose of both actives is essential.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated compounding and ampoule filling lines, control of the dual-active stability-indicating assay, the related-substance profile of each active, solution pH, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, dual-active stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Tolperisone Lidocaine Injection Demands a Premium Manufacturer
Tolperisone Lidocaine Injection holds a practical, everyday place in neurology clinics, rehabilitation and physical-medicine units, orthopaedic wards and pain services across many markets. It is the muscle relaxant that clinicians reach for when a patient's pain is being driven by pathologically increased muscle tone — the painful spasticity that follows a stroke or spinal injury, the reflex spasm that locks up an injured or post-operative muscle, and the raised tone of conditions such as multiple sclerosis and cerebral palsy. What makes the product distinctive is that it pairs two actives with complementary jobs: tolperisone, a centrally acting muscle relaxant that calms over-active spinal reflex arcs and lowers muscle tone through a stabilising action on nerve membranes, and a small amount of lidocaine, a familiar local anaesthetic added specifically to take the sting out of an otherwise uncomfortable intramuscular injection so that patients tolerate repeated dosing. Because the injection delivers two actives at once to patients who often need a course of treatment, the dose from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose of both components.
That clinical reality places real demands on the manufacturer. Tolperisone Lidocaine Injection is a fixed-dose combination — typically 100 mg of tolperisone hydrochloride with 2.5 mg of lidocaine hydrochloride in each millilitre — so the assay must be exact for both actives and the fill volume accurate so that every ampoule delivers the labelled content of each component in the correct ratio. The two water-soluble hydrochloride salts are compounded into a clear, colourless aqueous solution at a controlled pH that keeps both molecules stable, and the solution must stay clear and free of visible and sub-visible particulates and low in endotoxin. Because two actives share one container, the manufacturer must run a stability-indicating method that resolves and quantifies tolperisone, lidocaine and the degradation products of each without interference, and must select and validate the right sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing. The class cautions — the risk of hypersensitivity and, rarely, anaphylactic reactions reported with injectable tolperisone, and the lidocaine-related contraindications — must be carried clearly on the label. Choosing a Tolperisone Lidocaine Injection manufacturer that treats the dual-active stability-indicating assay, the ratio and content uniformity of both actives, pH control, fill-volume accuracy, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Tolperisone Lidocaine Injection Manufacturer Apart
A world-class manufacturer of Tolperisone Lidocaine Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay that quantifies both tolperisone and lidocaine, with related-substance control of each active, by validated HPLC — a dual-active method is harder to develop and defend than a single-active one, and a fixed-combination product demands it — a robust, validated sterilisation and fill process that protects sterility, clarity, pH and the content uniformity of two actives in one solution, and tender-ready dossier support for a high-volume neurology and rehabilitation product procured through hospital-pharmacy and ministry-of-health channels. It starts with the actives — pharmacopoeial-grade tolperisone hydrochloride and lidocaine hydrochloride sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before either material enters production.
Compounding and filling then have to defend the assay, the clarity and the pH of a two-active solution. The bulk solution is compounded in water-for-injection with both hydrochloride salts at the controlled pH that keeps tolperisone and lidocaine stable, then sterile-filtered through 0.22 µm membrane and filled into ampoules — or vials — under ISO Class 5 conditions, with the validated sterilisation route locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of both tolperisone and lidocaine by validated HPLC, the related-substance profile of each, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intramuscular administration. Because the product is a fixed combination, assay accuracy for both actives, their correct ratio, content uniformity and container-closure integrity are validated together so the assay, ratio and clarity stay within specification across shelf life.
Quality Systems Behind Every Tolperisone Lidocaine Injection
Every Farbe Firma Tolperisone Lidocaine Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of both tolperisone and lidocaine against pharmacopoeial reference standards, control of the related substances of each active by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule format. Certificates of analysis are issued with full traceability back to each tolperisone and lidocaine API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because the product is a parenteral fixed combination and the assay, ratio and content uniformity of two actives, the related-substance profile, pH, particulate and endotoxin burden all drive efficacy and safety, we treat the dual-active stability-indicating assay, the ratio of tolperisone to lidocaine, the related-substance profile and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, so the assay of both actives, the pH and the clarity stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Tolperisone Lidocaine Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad neurology, rehabilitation and musculoskeletal small-volume parenteral portfolio. For Tolperisone Lidocaine Injection specifically, we supply the 100 mg + 2.5 mg per mL combination in ampoule presentations under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the dual-active stability-indicating-assay, related-substance, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability packages, dual-active stability-indicating method-validation data, sterilisation and container-closure reports, translated package inserts and artwork — including deep-intramuscular administration instructions and the hypersensitivity and lidocaine-related cautions — for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Tolperisone Lidocaine Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through dual API sourcing, the development of a stability-indicating method that resolves two actives, related-substance control for both tolperisone and lidocaine, controlled-pH formulation design, the choice between terminal sterilisation and aseptic filling, fill-volume and ratio accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a fixed-dose combination where the accuracy and ratio of two actives directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Tolperisone Lidocaine Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Tolperisone Lidocaine Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated compounding and ampoule filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Tolperisone Lidocaine Injection do you supply?
Our standard presentation is the fixed combination of 100 mg tolperisone hydrochloride with 2.5 mg lidocaine hydrochloride per 1 mL ampoule, given by deep intramuscular injection. Custom strengths, fill configurations, ampoule and vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Tolperisone Lidocaine Injection mainly used for?
Tolperisone Lidocaine Injection is used to relieve painful muscle spasm and the increased muscle tone (spasticity) that accompanies neurological and musculoskeletal disorders, such as after a stroke or spinal injury and in conditions like multiple sclerosis and cerebral palsy. Tolperisone is a centrally acting muscle relaxant and the added lidocaine reduces injection-site pain; Farbe Firma verifies the assay of both actives, their related-substance profiles, pH, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose. Because hypersensitivity reactions have been reported with injectable tolperisone, it is given with appropriate caution and labelling.
Can Farbe Firma support country-specific registrations for Tolperisone Lidocaine Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability packages, dual-active stability-indicating method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Tolperisone Lidocaine Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our neurology and rehabilitation small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments